A Universal Tolerance Platform

Advancing Stem Cell Research

Beyond transplantation, Medawar's work in hematopoietic stem-cell recovery and expansion has broad implications for the future of regenerative medicine and stem cell research. Our MTP generates a stem-cell pipeline that supports both clinical applications and high-value discovery research — enabling new insights into immune regulation, tolerance biology, and multi-organ regeneration.

Expanding the Reach of Tolerance

Our scalable therapeutic platform is designed to:

• Enable delayed tolerance in patients with pre-existing transplants
• Extract abundant, and high-quality source of hematopoietic stem cells.
• Extend immune tolerance beyond kidney transplantation to include liver, heart, and lung.

Medawar Therapeutics was founded on a simple but radical idea — that true immune tolerance can be achieved in humans, even long after organ transplantation. Our approach builds directly on decades of clinical immunology and was validated through the world's first demonstration of delayed immune tolerance after kidney transplantation — a clinical proof-of-concept showing that the immune system can be retrained to accept an existing graft as "self." -The Lancet (2022, 2024)

Our proprietary protocols integrate stem-cell mobilization, graft conditioning, and immune re-education — forming a unified framework we call the Medawar Tolerance Platform (MTP™).

This platform not only addresses the clinical unmet need of lifelong immunosuppression but also lays the groundwork for next-generation stem-cell–based medicine and tolerance therapies.